With the approval, Cosentyx becomes the first and only interleukin-17A (IL-17A) inhibitor approved in Europe for adults with ...
The newly approved regimen offers a chemotherapy-free perioperative approach and is authorised for use across all 27 EU ...
Allergan Aesthetics is presenting new clinical findings at AMWC Dubai.
Based on I CAN Phase III trial results from prespecified interim analysis in which Ultomiris demonstrated 43.4% reduction in ...
The initiative will initially focus on patients with desmoid tumors and neurofibromatosis type 1 with plexiform neurofibromas ...
Launched in collaboration with Ameelio Healthcare Private Limited, the laboratory is aimed at expanding access to affordable, ...
Speakers include Parizad A. Elchidana, ACG World; Dr. Kiran Marthak, Veeda Life Sciences; Dr. Ravikrishna Chebolu, CSIR ...
Prolific has reported a productivity milestone of 21 grams per litre in a 15-day intensified fed-batch run for a monoclonal ...
Biotech firm Zealand Pharma has reported positive Phase 1 multiple ascending dose (MAD) results for ZP9830, its ...
The initiative aims to address persistent gaps in healthcare, including late diagnosis, delays in specialist referrals ...
Eli Lilly and Company has reported positive one-year results from a Phase 3 trial of Omvoh (mirikizumab-mrkz) in children and adolescents aged 6 to 17 with moderately to severely active ulcerative ...
AbbVie’s investigational dual-targeting therapy ABBV-466 has demonstrated higher rates of endoscopic remission than either of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results